523 related articles for article (PubMed ID: 31847543)
21. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Chen JY; Lai YS; Tsai HJ; Kuo CC; Yen BL; Yeh SP; Sun HS; Hung WC
Sci Rep; 2016 Aug; 6():32428. PubMed ID: 27577048
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
23. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
24. Hypoxia Induces Production of L-2-Hydroxyglutarate.
Intlekofer AM; Dematteo RG; Venneti S; Finley LW; Lu C; Judkins AR; Rustenburg AS; Grinaway PB; Chodera JD; Cross JR; Thompson CB
Cell Metab; 2015 Aug; 22(2):304-11. PubMed ID: 26212717
[TBL] [Abstract][Full Text] [Related]
25. SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2.
Smolková K; Špačková J; Gotvaldová K; Dvořák A; Křenková A; Hubálek M; Holendová B; Vítek L; Ježek P
Sci Rep; 2020 May; 10(1):8677. PubMed ID: 32457458
[TBL] [Abstract][Full Text] [Related]
26. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice.
Akbay EA; Moslehi J; Christensen CL; Saha S; Tchaicha JH; Ramkissoon SH; Stewart KM; Carretero J; Kikuchi E; Zhang H; Cohoon TJ; Murray S; Liu W; Uno K; Fisch S; Jones K; Gurumurthy S; Gliser C; Choe S; Keenan M; Son J; Stanley I; Losman JA; Padera R; Bronson RT; Asara JM; Abdel-Wahab O; Amrein PC; Fathi AT; Danial NN; Kimmelman AC; Kung AL; Ligon KL; Yen KE; Kaelin WG; Bardeesy N; Wong KK
Genes Dev; 2014 Mar; 28(5):479-90. PubMed ID: 24589777
[TBL] [Abstract][Full Text] [Related]
27. Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Kingsbury JM; Shamaprasad N; Billmyre RB; Heitman J; Cardenas ME
Hum Mol Genet; 2016 Aug; 25(16):3524-3538. PubMed ID: 27427385
[TBL] [Abstract][Full Text] [Related]
28. Quantitative Analysis of Oncometabolite 2-Hydroxyglutarate.
Yuan BF
Adv Exp Med Biol; 2021; 1280():161-172. PubMed ID: 33791981
[TBL] [Abstract][Full Text] [Related]
29. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A; Menendez JA
Carcinogenesis; 2019 Mar; 40(1):27-40. PubMed ID: 30428017
[TBL] [Abstract][Full Text] [Related]
30. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
[TBL] [Abstract][Full Text] [Related]
31. Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila.
Reitman ZJ; Sinenko SA; Spana EP; Yan H
Blood; 2015 Jan; 125(2):336-45. PubMed ID: 25398939
[TBL] [Abstract][Full Text] [Related]
32. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
[TBL] [Abstract][Full Text] [Related]
33. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia.
Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S
Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803
[TBL] [Abstract][Full Text] [Related]
34. Oncometabolite d-2HG alters T cell metabolism to impair CD8
Notarangelo G; Spinelli JB; Perez EM; Baker GJ; Kurmi K; Elia I; Stopka SA; Baquer G; Lin JR; Golby AJ; Joshi S; Baron HF; Drijvers JM; Georgiev P; Ringel AE; Zaganjor E; McBrayer SK; Sorger PK; Sharpe AH; Wucherpfennig KW; Santagata S; Agar NYR; Suvà ML; Haigis MC
Science; 2022 Sep; 377(6614):1519-1529. PubMed ID: 36173860
[TBL] [Abstract][Full Text] [Related]
35. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
36. Background levels of neomorphic 2-hydroxyglutarate facilitate proliferation of primary fibroblasts.
Dvořák A; Zelenka J; Smolková K; Vítek L; JeŽek P
Physiol Res; 2017 May; 66(2):293-304. PubMed ID: 27982681
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
38. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
39. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis.
Terunuma A; Putluri N; Mishra P; Mathé EA; Dorsey TH; Yi M; Wallace TA; Issaq HJ; Zhou M; Killian JK; Stevenson HS; Karoly ED; Chan K; Samanta S; Prieto D; Hsu TY; Kurley SJ; Putluri V; Sonavane R; Edelman DC; Wulff J; Starks AM; Yang Y; Kittles RA; Yfantis HG; Lee DH; Ioffe OB; Schiff R; Stephens RM; Meltzer PS; Veenstra TD; Westbrook TF; Sreekumar A; Ambs S
J Clin Invest; 2014 Jan; 124(1):398-412. PubMed ID: 24316975
[TBL] [Abstract][Full Text] [Related]
40. Metabolic consequences of oncogenic IDH mutations.
Parker SJ; Metallo CM
Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]